Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age.

The Journal of Immunology : Official Journal of the American Association of Immunologists
Sarah BurlKatie L Flanagan

Abstract

Bacillus Camette-Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis, yet its protective efficacy is highly variable between different geographical regions. We hypothesized that exposure to nontuberculous mycobacteria attenuates BCG immunogenicity by inducing mycobacterial-specific regulatory T cells (Tregs). Gambian neonates were recruited at birth and randomized to receive BCG vaccination either at birth or at 4 1/2 mo. Mycobacterial immune responses were assessed at birth, 4 1/2, and 9 mo of age. At 4 1/2 mo of age the BCG naive individuals had detectable mycobacterial responses, including increased IL-10 production suggesting environmental priming. Vaccination at birth significantly enhanced Th1, Th2, IL-6, IL-17, and Treg responses in mycobacterial cultures at 4 1/2 mo compared with the BCG naive group. Analyzing results at 4 1/2 mo postvaccination revealed lower IFN-gamma, IL-6, and IL-17 responses in the delayed BCG vaccine group compared with those vaccinated at birth, but this did not relate to Treg levels prevaccination. When comparing responses pre- and post-BCG vaccination in the delayed vaccine group, there was no priming of mycobacterial IL-17. Mycobacterial responses waned over 9 mo in those va...Continue Reading

References

Oct 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·J A BennettM S Mitchell
Apr 1, 1992·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·C S Muir, P A McKinney
Jan 1, 1992·Archives of Disease in Childhood·I IldirimB Cavuşoğlu
Oct 1, 1989·The American Review of Respiratory Disease·H F PabstM Grace
Sep 1, 1981·Reviews of Infectious Diseases·J G Weiszfeiler, V Karasseva
Oct 1, 1995·International Journal of Epidemiology·C LanckrietN Guérin
May 3, 2000·The Journal of Clinical Investigation·V A BoussiotisA E Goldfeld
Sep 6, 2000·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·J TurnerH M Dockrell
Sep 30, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D SmithV Balasubramanian
May 12, 2001·Vaccine·C A Siegrist
Jan 5, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Martin O C OtaArnaud Marchant
Jan 18, 2003·Science·Chandrashekhar Pasare, Ruslan Medzhitov
Mar 5, 2003·Annual Review of Immunology·Thomas A Wynn
Jan 23, 2004·Genes and Immunity·M J NewportUNKNOWN MRC Gambia Twin Study Group
Feb 25, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shigeki NabeshimaJun Hayashi
Mar 19, 2005·The Journal of Infectious Diseases·Sandra M ArendDick van Soolingen
Feb 8, 2006·Annals of the New York Academy of Sciences·Willem A Hanekom

❮ Previous
Next ❯

Citations

May 25, 2011·The Journal of Infectious Diseases·Thomas J ScribaHelen McShane
Sep 2, 2011·The Journal of Infectious Diseases·Maeve K LalorHazel M Dockrell
Jun 16, 2012·International Journal of Biological Sciences·Mercedes R RinconElizabeth A Bonney
Dec 18, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen McShane
Jan 15, 2011·Clinical & Developmental Immunology·Abdullah A AlangariJean-Laurent Casanova
Sep 17, 2015·Human Vaccines & Immunotherapeutics·Qingqing LiZhibin Yao
Mar 24, 2016·Human Vaccines & Immunotherapeutics·Yu PangSuhua Zheng
May 13, 2015·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Beate Kampmann, Christine E Jones
Oct 14, 2014·Frontiers in Microbiology·Jorjoh Ndure, Katie L Flanagan
Sep 19, 2014·Frontiers in Immunology·Ismé De KleerStanislas Goriely
Aug 12, 2014·The Journal of Infectious Diseases·Christophe Toukam TchakouteHeather B Jaspan
Aug 12, 2014·The Journal of Infectious Diseases·Alexander W Kay, Catherine A Blish
Jul 21, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fatou Noho-KontehKatie L Flanagan
Oct 16, 2014·Memórias do Instituto Oswaldo Cruz·Renata Monteiro-Maia, Rosa Teixeira de Pinho
May 25, 2011·Expert Review of Vaccines·Rosalind Rowland, Helen McShane
Nov 6, 2013·Transboundary and Emerging Diseases·B M BuddleA Heiser
Sep 12, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T N NissenO Pryds
Jan 29, 2020·The Journal of Infectious Diseases·Bridget FreyneUNKNOWN Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) Group
Sep 29, 2017·Frontiers in Immunology·Hazel M Dockrell, Steven G Smith
Mar 25, 2011·Mucosal Immunology·J L FlynnP L Lin
Oct 14, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elisa NemesUNKNOWN MVA029 Study Team
Mar 20, 2020·Seminars in Immunopathology·Benedict Brazier, Helen McShane
Mar 13, 2020·JCI Insight·Rajesh Kumar RadhakrishnanRamakrishna Vankayalapati
Mar 15, 2019·Clinical Microbiology Reviews·Petra Zimmermann, Nigel Curtis
May 7, 2021·Immunological Reviews·Asma AhmedAnnapurna Vyakarnam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.